Clinical trial
Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic…
NCT00020540 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00020540 |
|---|---|
| Title | Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer |
| Official title | Treatment Of Patients With Metastatic Melanoma And Renal Cancer With A Combination Of Flt3L And CD40L |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Kidney Cancer, Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | recombinant CD40-ligand, recombinant flt3 ligand |
| Start date | Mar 1, 2001 |
| First posted | Apr 5, 2004 |
| Last update posted | Apr 30, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: